Serum levels of Matrix Extracellular Phosphoglycoprotein (MEPE) in normal humans correlate with serum phosphorus, parathyroid hormone and bone mineral density

Journal of Clinical Endocrinology and Metabolism

Volumn 89, Issue 8, 2004, Pages 4158-4161

  Jain, A ^a   Fedarko, N S ^a   Collins, M T ^c   Gelman, R ^b   Ankrom, M A ^a   Tayback, M ^b   Fisher, L W ^c  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS BAYVIEW MEDICAL CENTER   (United States)

^c NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN; MATRIX EXTRACELLULAR PHOSPHOGLYCOPROTEIN; PARATHYROID HORMONE; UNCLASSIFIED DRUG;

ADULT; AGED; AGING; ARTICLE; BONE MINERAL; CORRELATION ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR MATRIX; FEMALE; FEMUR NECK; HIP; HUMAN; IMMUNOASSAY; MALE; NORMAL HUMAN; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL;

ADULT; AGED; AGING; BONE DENSITY; ENZYME-LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR MATRIX PROTEINS; FEMUR NECK; GLYCOPROTEINS; HIP JOINT; HUMANS; PARATHYROID HORMONE; PHOSPHOPROTEINS; PHOSPHORUS; REFERENCE VALUES;

EID: 4043120646     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.2003-032031     Document Type: Article

References (19)

1. Fisher LW, Torchia DA, Fohr B, Young MF, Fedarko NS 2001 The solution structures of two SIBLING proteins, bone sialoprotein and osteopontin, by NMR. Biochem Bophys Res Comm 280:460-465
2. Fisher LW, Fedarko NS 2003 Six genes expressed in bones and teeth constitute the current members of the SIBLING family of proteins. Connective Tissue Res. 44:1-8
3. Rowe PS, de Zoysa PA, Dong R, Wang HR, White KE, Econs MJ, Oudet CL 2000 MEPE, a new gene expressed in bone marrow and tumors causing osteomalacia. Genomics 67:54-68
4. Argiro L, Desbarats M, Glorieux FH, Ecarot B 2001 Mepe, the gene encoding a tumor-secreted protein in oncogenic hypophosphatemic osteomalacia, is expressed in bone. Genomics 74:342-51
5. Quarles LD 2003 FGF23, PHEX, and MEPE regulation of phosphate homeostasis and skeletal mineralization. Am J Physiol Endocrinol Metab 285:E1-9
6. Gowen LC, Petersen DN, Mansolf AL, Qi H, Stock JL, Tkalcevic GT, Simmons HA, Crawford DT, Chidsey-Frink KL, Ke HZ, McNeish JD, Brown TA 2003 Targeted disruption of the osteoblast/osteocyte factor 45 gene (OF45) results in increased bone formation and bone mass. J Biol Chem 278:1998-2007
7. Fedarko NS, Fohr B, Gehron Robey P, Young MF, Fisher LW 2000 Factor H binding to bone sialoprotein and osteopontin enables molecular cloaking of tumor cells from complement-mediated attack. J Biol Chem 275:16666-16672
8. Jain A, Karadag A, Fohr B, Fisher LW, Fedarko NS 2002 Three Small Integrin Binding LIgands N-linked Glycoproteins (SIBLINGS) enhance Factor H's cofactor activity enabling MCP-like cellular evasion of complement-mediated attack. J Biol Chem 277:13700-13708
9. Fedarko NS, Jain A, Karadag A, Van Eman MR, Fisher LW 2001 Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer. Clin Cancer Res 7:4060-6
10. Towbin H, Staehelin T, Gordon J 1979 Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci U S A 76:4350-4
11. Mazzachi BC, Peake MJ, Ehrhardt V 2000 Reference range and method comparison studies for enzymatic and Jaffe creatinine assays in plasma and serum and early morning urine. Clin Lab 46:53-55
12. Daly JA, Ertingshausen G 1972 Direct method for determining inorganic phosphate in serum with the "CentrifiChem". Clin Chem 18:263-5
13. Petersen DN, Tkalcevic GT, Mansolf AL, Rivera-Gonzalez R, Brown TA 2000 Identification of osteoblast/osteocyte factor 45 (OF45), a bone- specific cDNA encoding an RGD-containing protein that is highly expressed in osteoblasts and osteocytes. J Biol Chem 275:36172-80
14. Riminucci M, Collins MT, Fedarko NS, Cherman N, Corsi A, White KE, Waguespack S, Gupta A, Hannon T, Econs MJ, Bianco P, Gehron Robey P 2003 FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting. J Clin Invest 112:683-92
15. Shimada T, Mizutani S, Muto T, Yoneya T, Hino R, Takeda S, Takeuchi Y, Fujita T, Fukumoto S, Yamashita T 2001 Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci U S A 98:6500-5
16. White KE, Carn G, Lorenz-Depiereux B, Benet-Pages A, Strom TM, Econs MJ 2001 Autosomal-dominant hypophosphatemic rickets (ADHR) mutations stabilize FGF-23. Kidney Int 60:2079-86
17. Berndt T, Craig TA, Bowe AE, Vassiliadis J, Reczek D, Finnegan R, Jan De Beur SM, Schiavi SC, Kumar R 2003 Secreted frizzled-related protein 4 is a potent tumor-derived phosphaturic agent. J Clin Invest 112:785-94
18. Rowe PS, Kumagai Y, Gutierrez G, Garrett IR, Blacher R, Rosen D, Cundy J, Navvab S, Chen D, Drezner MK, Quarles LD, Mundy GR 2004 MEPE has the properties of an osteoblastic phosphatonin and minhibin. Bone 34:303-19
19. Hayashibara T, Hiraga T, Yi B, Nomizu M, Kumagai Y, Nishimura R, Yoneda T 2004 A synthetic peptide fragment of human MEPE stimulates new bone formation in vitro and in vivo. J Bone Miner Res 19:455-62